摘要
A20最初是作为肿瘤坏死因子α(TNFα)诱导蛋白3(TNFA IP3)而鉴定的,它是炎症信号传导的中心调节因子———NF-κB抑制因子,在天然免疫和过继性免疫调节中发挥了重要作用。近期研究提示,A20是一个肿瘤抑制因子。A20缺失与炎症介导的自身免疫性疾病和淋巴细胞肿瘤的发生发展关系密切。近期有关A20在免疫细胞中的表达特点和生物学功能,在天然免疫、体液和细胞免疫中的调节作用,在淋巴细胞肿瘤中缺失情况以及在自身免疫性疾病中的异常表达等等的研究进展提示:有必要深入认识A20的临床意义和探讨其在诱导免疫耐受、肿瘤免疫调节治疗和抗病毒治疗等方面的应用价值。
A20 was originally identified as a TNFα-induced protein 3 （ TNFAIP3 ）, a key regulator of infammafion signalling pathways, as well as a NF-κB inhibitor. It plays a critical role in regulation of innate and adoptive immunity. Recently, A20 has also been proposed to function as a tumor suppressor. Lacking A20 gene is involved in inflammationmediated autoimmune disease and tumorigenesis in several human B-cell lymphomas. Current advance concerning the feature of A20 expression in immune cells, the biological function, the immune regulated function in native immunity, humoral and cellular immunity, the inactivation of A20 in lymphocytical malignancies and the polymorphism and abnormal expression of A20 in autoimmune disease indicate that the clinical significance of A20 should be worthly to recognize and to be further employed in induction of immune tolerance, antitumor immuno-regnlated therapy and antiviral immunotherapy and so on.
出处
《中国实验血液学杂志》
CAS
CSCD
2011年第4期851-856,共6页
Journal of Experimental Hematology
基金
国家自然科学基金资助项目(编号30871091)
中央高校基本科研业务费专项资金资助项目(编号21610603)
